PF 04457845

Drug Profile

PF 04457845

Alternative Names: PF-04457845; PF-4457845

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Developer Linkoping University; Pfizer; Stockholm Centre for Dependency Disorders
  • Class Benzylidene compounds; Piperidines; Pyridazines; Small molecules
  • Mechanism of Action Fatty acid amide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Psychiatric disorders
  • Discontinued Alcoholism; Pain; Post-traumatic stress disorders

Most Recent Events

  • 28 Feb 2017 Phase-II clinical trials in Psychiatric disorders (In volunteers) in Sweden (PO) (EudraCT2016-005013-47)
  • 28 Oct 2015 Discontinued - Phase-II for Alcoholism in Sweden (PO)
  • 28 Oct 2015 Discontinued - Phase-II for Post-traumatic stress disorder in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top